The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C infection in children aged 12 and older.

Both Solvaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are already approved for use in adults, the agency said in a news release Friday.

The medications are antivirals that prevent the hepatitis C virus (HCV) from reproducing. “In most cases, they cure HCV,” the FDA added.

“These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents,” said Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.